[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344919-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344919-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","il-15-enhances-preclinical-efficacy-of-anti-core-1-o-glycans-monoclonal-antibody-neo-201-against-human-endometrial-and-ovarian-cancer","IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer","","Resistance of gynecological cancers to immunotherapy is linked to impaired cytotoxic activity of immune cells. O-glycosylation pathway disruption in ovarian and endometrial cancer correlates with cancer growth, metastasis, and poor prognosis. The study evaluates in vitro and in vivo effects of combining NEO-201 with IL-15 to counter immunotherapy resistance, focusing on enhanced ADCC and related killing mechanisms. Results show IL-15 strengthens NEO-201-mediated ADCC in target-expressing cancer cell lines and yields a modest survival benefit in a mouse ovarian cancer model, supporting combination strategies involving IL-15 and NEO-201 with NK cell approaches.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/il-15-enhances-preclinical-efficacy-of-anti-core-1-o-glycans-monoclonal-antibody-neo-201-against-human-endometrial-and-ovarian-cancer/344919/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/il-15-enhances-preclinical-efficacy-of-anti-core-1-o-glycans-monoclonal-antibody-neo-201-against-human-endometrial-and-ovarian-cancer/344919.png","ImageObject",300,407,{"name":42,"@type":43},"Ava Thompson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study target in gynecological cancers?","Question",{"text":63,"@type":64},"It targets immunotherapy resistance in gynecological cancers, attributed to impaired cytotoxic activity of immune cells and associated tumor biology.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were IL-15 and NEO-201 combined in the experiments?",{"text":68,"@type":64},"Human endometrial and ovarian cancer cell lines were treated in vitro with the monoclonal antibody NEO-201 plus IL-15, and the combination was also tested in vivo in mice bearing human ovarian cancer.",{"name":70,"@type":61,"acceptedAnswer":71},"What main efficacy effects were observed with IL-15 plus NEO-201?",{"text":72,"@type":64},"IL-15 enhanced NEO-201-mediated ADCC in vitro against target antigen-expressing cancer cell lines, and the combination modestly prolonged survival in the mouse ovarian cancer model compared with either agent alone.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344919,1790186852,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","TYPE Original Research PUBLISHED 24 February 2026  \nDOI 10.3389/fimmu.2026.1652596  \nOPEN ACCESS  \nEDITED BY  \nAnna Passarelli,  \nG. Pascale National Cancer Institute Foundation (IRCCS), Italy  \nREVIEWED BY  \nZongde Zhang,  \nSouthwest Medical University, China Elin Bernson,  \nUniversity of Gothenburg, Sweden  \n*CORRESPONDENCE  \nMassimo Fantini  \n massimo.fantini@precision[biologics.com](biologics.com)  \nMaria Pia Morelli  \n [MPMorelli@mdanderson.org](MPMorelli@mdanderson.org)  \nRECEIVED 23 June 2025  \nREVISED 17 January 2026  \nACCEPTED 02 February 2026  \nPUBLISHED 24 February 2026  \nCITATION  \nHur J, Fantini M, Hernandez L, Korrapati S, Edmondson EF, Cam M, Tandon M, Cole CB, Tsang KY, Arlen PM, Annunziata CM and Morelli MP (2026) IL 15 enhances preclinical efﬁcacy of anticore 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer.  \nFront. Immunol. 17:1652596 .  \ndoi: 10.3389/fimmu.2026.1652596  \nCOPYRIGHT  \n© 2026 Hur, Fantini, Hernandez, Korrapati, Edmondson, Cam, Tandon, Cole, Tsang, Arlen, Annunziata and Morelli. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nIL 15 enhances preclinical efﬁcacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer  \nJamie Hur 1, Massimo Fantini 2*, Lidia Hernandez 1,  \nSoumya Korrapati 1, Elijah F. Edmondson 3, Maggie Cam 4, Mayank Tandon4,5, Christopher B. Cole 1, Kwong Y. Tsang 2, Philip M. Arlen 2, Christina M. Annunziata 1 and Maria Pia Morelli 6*  \n1Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States, 2 Precision Biologics, Inc., Bethesda, MD, United States, 3 Molecular Histopathology Laboratory, Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD, United States, 4Center for Cancer Research Collaborative Bioinformatics Resource (CCBR), National Cancer Institute, National Institutes of Health, Bethesda, MD, United States, 5Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, United States, 6 Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States  \nBackground: Resistance of gynecological cancers to immunotherapy is due to their ability to impair the cytotoxic activity of immune cells. One strategy to overcome this resistance is the combination of different types of immunotherapies with different mechanisms of action and different targets. The disruption of O-glycosylation pathway in ovarian and endometrial cancer is associated with cancer growth, metastasis, and poor prognosis.  \nMethods: In this study we treated in vitro endometrial and ovarian human cancer cell lines with the combination of the monoclonal antibody (mAb) NEO-201 and IL-15 to overcome the resistance of gynecological cancers to immunotherapy. The combination was also used in vivo to treat mice bearing human ovarian cancer. NEO-201 is a humanized IgG1 mAb that binds to core 1 and/or extended core 1 O-glycans expressed by human cancer cells (including different ovarian cancer subtypes), as well as non-cancerous CD15 + granulocytes and immunosuppressive cells. NEO-201 can mediate the killing of its target cells through different mechanisms of action, including antibody-dependent cellmediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) . One strategy to enhance ADCC mediated by mAbs is to boost natural killer (NK) cells with IL-15 . A previous study showed that IL-15 su","cbCaipOSSOF8aZ6H","https://ap.wps.com/l/cbCaipOSSOF8aZ6H","pdf",9754995,14,"English","# Background\n## Methods and treatment strategy\n# Results\n# Conclusions","[{\"question\":\"What problem does the study target in gynecological cancers?\",\"answer\":\"It targets immunotherapy resistance in gynecological cancers, attributed to impaired cytotoxic activity of immune cells and associated tumor biology.\"},{\"question\":\"How were IL-15 and NEO-201 combined in the experiments?\",\"answer\":\"Human endometrial and ovarian cancer cell lines were treated in vitro with the monoclonal antibody NEO-201 plus IL-15, and the combination was also tested in vivo in mice bearing human ovarian cancer.\"},{\"question\":\"What main efficacy effects were observed with IL-15 plus NEO-201?\",\"answer\":\"IL-15 enhanced NEO-201-mediated ADCC in vitro against target antigen-expressing cancer cell lines, and the combination modestly prolonged survival in the mouse ovarian cancer model compared with either agent alone.\"}]","IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer | PDF",1790055765,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/314fc6909df1ceb55a9b65576d561698.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9bf5b64779a917ce5090cddaa5b6b09.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b03540d45b76e3834b1ad7af816fa73.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cf4bf2f8c63c4e06f5c11ecd9194380.webp",980,1385]